Decorin suppresses tumor cell-mediated angiogenesis
Derrick S Grant1, Cigdem Yenisey, R Wesley Rose
1Cardeza Foundation for Hematologic Research, Department of Medicine, Thomas Jefferson University, Room 812 Curtis Building, 1015 Walnut Street, Philadelphia, Pennsylvania, PA 19107, USA.
Oncogene
|July 9, 2002
Summary
Decorin suppresses tumor growth by inhibiting angiogenesis. This protein reduces vascular endothelial growth factor (VEGF) production, a key factor in new blood vessel formation essential for tumor expansion.
Area of Science:
- Oncology
- Molecular Biology
- Angiogenesis Research
Background:
- Tumor growth relies on new blood vessel formation (angiogenesis).
- Tumor-secreted factors and matrix proteins regulate angiogenesis.
- Decorin is a matrix protein with potential roles in tumor biology.
Purpose of the Study:
- To investigate the effect of decorin on angiogenesis in various tumor cells.
- To determine the impact of decorin on endothelial cell behavior in vitro and in vivo.
- To elucidate the mechanism by which decorin influences tumor growth and neovascularization.
Main Methods:
- Assessing endothelial cell migration, attachment, and differentiation in vitro.
- Evaluating endothelial cell sprouting using an ex vivo aortic ring assay.
- Analyzing tumor xenograft growth rates and neovascularization in nude mice.
- Measuring vascular endothelial growth factor (VEGF) mRNA and protein levels via immunohistochemistry, Northern, and Western blot analyses.
Main Results:
- Wild-type tumor cell secretions promoted endothelial cell functions, while decorin-expressing cells inhibited them.
- Decorin suppressed endothelial cell sprouting in aortic ring assays.
- Decorin-expressing tumor xenografts exhibited reduced growth rates and suppressed neovascularization.
- Decorin significantly decreased VEGF production in tumor cells, both endogenously and when added exogenously.
Conclusions:
- Decorin inhibits angiogenesis by suppressing tumor cell production of VEGF.
- Decorin has a novel mechanism of action impacting tumor growth.
- Decorin demonstrates potential as an anti-angiogenic agent to control tumor expansion.
Related Concept Videos
01:10Mechanism of Angiogenesis
6.7K
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
6.7K
01:24Regulation of Angiogenesis and Blood Supply
3.3K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.3K
02:34Inhibition of Cdk Activity
5.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.6K
01:27Tumor Immunotherapy
1.8K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.8K
02:07Tumor Progression
7.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.2K
01:10Drugs that Destabilize Microtubules
3.6K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
3.6K